More than half of all patients treated with glaucoma medications have ocular surface disease, which predominantly manifests as dry eye disease.
Glaucoma treatment has been associated with higher levels of ocular surface alterations and inflammatory markers, which may explain the relationship between dry eye disease (DED) and glaucoma.
An 82-year-old woman diagnosed with primary open-angle glaucoma for more than 10 years had received a topical regimen of timolol, brimonidine tartrate and latanoprost to manage her glaucoma. Previously, she had received artificial tears, over-the-counter